Chutzpah Goes Unrewarded
Client Alert | less than 1 min read | 02.24.06
The contractor in Armour of Am. v. U.S. (CFC Feb. 14, 2006) alleged "no cause of action" when it argued that it should not have been terminated for default when it was obvious from its offer that it could not meet the mandatory requirements of the RFP/contract and the FAR required the agency to reject nonconforming offers. Still alive, though, is the issue of whether the agency breached its good faith duties by making the award with actual knowledge of the nonconformity and then defaulting early on in the program.
Insights
Client Alert | 4 min read | 05.01.26
Federal Court Blocks Trump Administration Policies Restricting Wind and Solar Permitting
A coalition of regional clean energy trade associations — including RENEW Northeast, Alliance for Clean Energy New York, Southern Renewable Energy Association, and Interwest Energy Alliance — along with the Green Energy Consumers Alliance (GECA), filed suit in December 2025 against the Department of the Interior (DOI), the Bureau of Land Management, the Bureau of Ocean Energy Management, the U.S. Fish and Wildlife Service (USFWS), and the Army Corps of Engineers. The complaint alleged that five agency actions, issued in response to a series of executive orders and presidential memoranda beginning on January 20, 2025, violated the Administrative Procedure Act (APA) by arbitrarily halting or restricting federal permitting for wind and solar energy projects. Plaintiffs sought a preliminary injunction to halt enforcement of these policies while the litigation proceeds. See Renew Northeast, et al. v. U.S. Dep’t of Interior, et al., No. 25-cv-13961-DJC, (D. Mass. Apr. 21, 2026) ECF Dkt. 89.
Client Alert | 2 min read | 05.01.26
New Executive Order Promoting Fixed Price Contracting: What It Means for Federal Contractors
Client Alert | 8 min read | 05.01.26
Pre-Approved: ICO Publishes Guidance on "Recognised Legitimate Interests”
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
